Biodexa Pharmaceuticals Plc (BDRX) Form 6-K — Nov 9, 2026
Biodexa Pharmaceuticals (Nasdaq: BDRX) announced that its registrational Phase 3 Serenta trial of eRapa in familial adenomatous polyposis (FAP) has enrolled 112 of an expected 168 participants across 29 clinical sites in the US and Europe. Based on the current rate of progression-free survival events, the pre-specified futility analysis could occur in early 2027 with database lock around the end of 2027 — significantly sooner than originally anticipated.
Key figures
- Clinical sites
- 29
- Countries with sites
- 6
- Expected participants
- 168
- Participants enrolled
- 112
- Pfs events for database lock
- 75
- Pfs events for futility analysis
- 25
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.